Clinical Trial Update: The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, effectiveness, and pharmacokinetics of AA4500 for edematous fibrosclerotic panniculopathy (cellulite) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellulite
• Edematous Fibrosclerotic Panniculopathy

Drugs mentioned

• AA4500

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 1 | Status: COMPLETED